Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
Total Valuation
Bioxcel Therapeutics has a market cap or net worth of $36.54M. The enterprise value is $104.56M.
Market Cap$36.54M
Enterprise Value$104.56M
Share Statistics
Bioxcel Therapeutics has 19,646,801 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,646,801
Owned by Insiders2.95%
Owned by Institutions1.61%
Financial Efficiency
Bioxcel Therapeutics’s return on equity (ROE) is 0.64 and return on invested capital (ROIC) is -399.01%.
Return on Equity (ROE)0.64
Return on Assets (ROA)-1.55
Return on Invested Capital (ROIC)-399.01%
Return on Capital Employed (ROCE)-4.18
Revenue Per Employee61.24K
Profits Per Employee-1.61M
Employee Count37
Asset Turnover0.06
Inventory Turnover3.16
Valuation Ratios
The current PE Ratio of Bioxcel Therapeutics is ―. Bioxcel Therapeutics’s PEG ratio is 0.00334.
PE Ratio―
PS Ratio6.69
PB Ratio-0.16
Price to Fair Value-0.16
Price to FCF-0.21
Price to Operating Cash Flow-0.26
PEG Ratio0.00334
Income Statement
In the last 12 months, Bioxcel Therapeutics had revenue of 2.27M and earned -59.60M in profits. Earnings per share was -23.51.
Revenue2.27M
Gross Profit123.00K
Operating Income-67.25M
Pretax Income-59.60M
Net Income-59.60M
EBITDA-44.16M
Earnings Per Share (EPS)-23.51
Cash Flow
In the last 12 months, operating cash flow was -58.21M and capital expenditures 0.00, giving a free cash flow of -58.21M billion.
Operating Cash Flow-58.21M
Free Cash Flow-58.21M
Free Cash Flow per Share-2.96
Dividends & Yields
Bioxcel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.49
52-Week Price Change-81.51%
50-Day Moving Average2.38
200-Day Moving Average2.39
Relative Strength Index (RSI)37.78
Average Volume (3m)1.58M
Important Dates
Bioxcel Therapeutics upcoming earnings date is Mar 5, 2026, TBA (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 5, 2026
Ex-Dividend Date―
Financial Position
Bioxcel Therapeutics as a current ratio of 1.68, with Debt / Equity ratio of -100.95%
Current Ratio1.68
Quick Ratio1.65
Debt to Market Cap6.79
Net Debt to EBITDA-1.66
Interest Coverage Ratio-4.44
Taxes
In the past 12 months, Bioxcel Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bioxcel Therapeutics EV to EBITDA ratio is -2.00, with an EV/FCF ratio of -1.23.
EV to Sales38.95
EV to EBITDA-2.00
EV to Free Cash Flow-1.23
EV to Operating Cash Flow-1.23
Balance Sheet
Bioxcel Therapeutics has $37.32M in cash and marketable securities with $109.29M in debt, giving a net cash position of -$71.97M billion.
Cash & Marketable Securities$37.32M
Total Debt$109.29M
Net Cash-$71.97M
Net Cash Per Share-$3.66
Tangible Book Value Per Share-$36.73
Margins
Gross margin is -151.61%, with operating margin of -2967.56%, and net profit margin of -2630.14%.
Gross Margin-151.61%
Operating Margin-2967.56%
Pretax Margin-2630.14%
Net Profit Margin-2630.14%
EBITDA Margin-1948.85%
EBIT Margin-1962.49%
Analyst Forecast
The average price target for Bioxcel Therapeutics is $10.67, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$10.67
Price Target Upside513.22% Upside
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast-66.96%
EPS Growth Forecast71.83%